Search
+
    SEARCHED FOR:

    GOLDMAN SACHS GROUP

    Goldman Sachs appoints Sudarshan Ramakrishnan and Devarajan Nambakam as the co-heads of Investment Banking in India

    Goldman Sachs has named Sudarshan Ramakrishnan and Devarajan Nambakam as co-heads of its investment banking business in India. Sunil Khaitan has also joined as managing director. Ramakrishnan and Nambakam will drive growth strategy, reporting to Sonjoy Chatterjee. The firm aims to leverage global expertise to deepen client relationships amidst India's economic growth.

    5 world market themes for the week ahead

    The upcoming week promises significant market activity with pressure on Joe Biden's election prospects, anticipation of a Fed rate cut, key Q2 earnings reports, an ECB meeting, and the unveiling of the UK legislative agenda by King Charles. Analysts and investors should brace for developments from the U.S., Europe, and China that could influence global markets.

    How Indian-American businessman duped Goldman Sachs of Rs 8,300 crore

    Rishi Shah, co-founder of Outcome Health, has been sentenced to seven and a half years in prison for his role in a $1 billion fraud scheme involving high-profile investors like Goldman Sachs and Google's parent company, Alphabet. The scheme, which included inflating advertising inventory and deceiving investors and clients, was uncovered in 2017. Shah's extravagant lifestyle, funded by fraudulent activities, included private jets and yachts. His sentencing marks the conclusion of one of the largest corporate fraud cases in recent history, highlighting the consequences of deceptive business practices.

    Wall Street’s $5.5 trillion triple-witching to test market calm

    This quarter’s expiration comes as implied volatility on S&P 500 options is holding near the lowest level since before the coronavirus pandemic, with the US benchmark index riding the surge in shares of Nvidia Corp. and other artificial intelligence-linked companies. The expiration coincides with index rebalancing, when S&P Dow Jones Indices shuffles company weightings and ETFs that track its gauges make similar adjustments.

    Ozempic frenzy lures rich Indians to brave the gray market

    People are going to great lengths to obtain popular weight-loss drugs. They are stashing injectables in their carry-on luggage, buying counterfeit formulas online, and importing boxes from Europe. The treatments have sparked extensive media coverage, fueling a high demand. According to Goldman Sachs Research, the anti-obesity medication market could hit $100 billion by 2030. In contrast, Indians have largely been observers in this global frenzy over the new weight-loss solutions.

    Wall Street bankers beaten in ‘Smartest’ chess tournament

    William Graif, a chess enthusiast, has competed in various countries and now focuses on teaching chess to children after participating in the World Corporate Chess Championship.

    The Economic Times
    BACK TO TOP